Skip to main content

Inrig Jula's Form 4 filing

Travere Therapeutics, Inc. (TVTX) · filed Feb 12, 2025

Accession no.
0001415889-25-003819
Filed
Feb 12, 2025
Trade date
Feb 10-12, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $60.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Inrig JulaCIK 0001902368Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 10, 2025Common StockMOption exerciseAcquired+8,000–F2–92,170Direct
Feb 12, 2025Common StockSSaleDisposed−2,568$23.53−$60,425.0489,602Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 10, 2025Common StockMOption exerciseDisposed−8,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)